Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... study published online today in the International Journal of Cancer. The study drug, Bortezomib, was found to be effective against bone cancer in human cancer cell studies and in mice. ...
2009 OCT 5 ... 'DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.' ...
2009 NOV 2 ... doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine ...
2009 SEP 28 ... in MM and T-cell leukemic cells. Combination of resveratrol with perifosine or bortezomib potentiated the apoptotic response induced by each single drug," wrote M. Reis-Sobreiro ...
2009 NOV 23 ... of pivotal proinflammatory cytokines in the pathogenesis of rheumatoid arthritis (RA). Bortezomib inhibits NF-kappa B activation by blocking the degradation of the NF-kappa B inhibitor, ...
2009 NOV 2 ... of rituximab as mono-therapy or in combination with cyclophosphamide, nucleoside analog, bortezomib, or thalidomide-based regimens can be considered for the first-line therapy of WM and ...
2009 OCT 5 ... Research findings, 'Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin ...
2009 OCT 12 ... (MM) and is associated with significant morbidity and increased early death rate. Bortezomib is active and well tolerated in patients with MM who present or develop renal ...
2009 OCT 12 ... the mechanistic basis for the antiproliferative effects of the proteasome inhibitor, bortezomib, in human clear cell renal cell cancer cells (CCRCC)," scientists writing in the ...
2009 OCT 12 ... Investigators publish new data in the report 'Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in ...
2009 NOV 23 ... Remissions trial, it proved that dose modification using a specific guideline improved bortezomib-induced peripheral neuropathy management. Peripheral neuropathy can be associated with ...
2009 NOV 23 ... According to recent research from the United States, "Bortezomib is a proteasome inhibitor that can synergize with interferon-alpha (IFN-alpha) to induce ...
2009 NOV 16 ... "These were proteasome inhibitors, including lactacystin, MG132, and PS-341 (Bortezomib/VELCADE), and direct inhibitors of NF-kappa B activity, including ethyl pyruvate (EP) ...
2009 SEP 28 ... a histone deacetylase inhibitor, enhances cell death by the proteasome inhibitor bortezomib in vitro. We sought to test the combination clinically." "A phase I trial ...
2009 OCT 5 ... the proteasome degradation pathway, we also show that inhibition of this pathway, using bortezomib, causes regression of CML-like disease. Bortezomib ...
2009 OCT 12 ... myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell ...
2009 NOV 16 ... mechanisms of action of PIs, we analyzed the proapoptotic activities of PIs (MG132 or Bortezomib) in NSCLC cells." "We found that both MG132 (>1 microM) and...
2009 NOV 2 ... patients, FGFR3-translocation bore no adverse effects on outcome in TT3 with added bortezomib. Del TP53, another poor-risk feature in TT2 and present in 10% of 441 patients treated, ...
